2008. METRO+-AZA

RCT/METRO+AZA/CD/Postop

Single center randomised controlled trial Patients with CD after surgery with at least 1 risk factor for recurrence were randomised to: Metronidazol (250mg/3times per day) for 3 months + azathioprine

(100mg if <60kg or 150mg if >60) for 12 months vs metronidazol for 3 months alone started 2 weeks after surgery

<u>Primary endpoints:</u> Endoscopic recurrence at month 3 and 12 (Rutgeerts >i1)

Results: N=81

- At 3 months, 34.3% (M+AZA) vs 52.6% (M+pbo) endoscopic recurrence, p=0.11
- Endosocpic recurrence at 12 months 43.7% (M+AZA) vs 69% (M+pbo), p=0.048
- ITT endoscopic recurrence 55% (M+AZA) vs 78% (M+pbo) at 12 months, p=0.035

Conclusion:

Concomitant AZA resulted in lower endoscopic recurrence rates and less severe recurrences 12 months post-surgery, predicting a more favorable clinical outcome. This combined treatment seems to be recommendable to all operated CD patients with an enhanced risk for recurrence.

Therapy of Metronidazole With Azathioprine to Prevent PostoperativeRecurrence of Crohn's Disease: A Controlled Randomized Trial

Endoscopic recurrence




Figure 2. Proportion of patients with significant endoscopic recurrence (grades i2, i3, and i4) at months 3 and 12 in both treatment groups.




Figure 3. Different stages of endoscopic recurrence in both patient groups at 3 and 12 months.

Z